Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis
- PMID: 37862078
- PMCID: PMC10771870
- DOI: 10.1089/apc.2023.0109
Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis
Abstract
Cabotegravir long-acting injectable HIV pre-exposure prophylaxis (LA PrEP) is efficacious, with a good safety profile, and was approved by the US Food and Drug Administration in December 2021. Understanding variations in potential user preferences for LA PrEP may inform implementation and subsequently improve uptake and community-level effectiveness. HIV-negative, sexually active men who have sex with men (MSM) aged ≥15 years were recruited online for the 2019 American Men's Internet Survey, before LA PrEP approval. Respondents completed a discrete-choice experiment (DCE) with hypothetical LA PrEP attributes (out-of-pocket cost, perceived side effects, injection frequency, perceived stigma, service location). Latent class analysis segmented respondents into groups based on their preferences for the attributes presented, and relative importance of preference weights and willingness-to-pay were calculated. While the majority had never used daily oral PrEP, 73% of the 2489 respondents were very or somewhat likely to use LA PrEP. Three latent classes were identified from 2241 respondents in the DCE. The "side effects-averse" class was the largest group (64% of respondents) and placed 61% relative importance on side effects. The "ambivalent" class (20% of respondents) placed higher importance on stigma (17% of relative importance) than other classes. The "cost-conscious" class (16% of respondents) placed higher relative importance (62%) on cost compared with other attributes and classes. Perceived side effects were an important hypothetical barrier for LA PrEP uptake among a large proportion of potential MSM users. Minimizing out-of-pocket costs is likely to increase uptake and may be important to equitable access. Tailored communication strategies are recommended for the different groups of potential LA PrEP users.
Keywords: HIV/AIDS; PrEP; discrete-choice experiment; prevention.
Conflict of interest statement
No competing financial interests exist.
Similar articles
-
Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.BMJ Open. 2024 Apr 22;14(4):e083837. doi: 10.1136/bmjopen-2023-083837. BMJ Open. 2024. PMID: 38653510 Free PMC article.
-
Identifying HIV PrEP Attributes to Increase PrEP Use Among Different Groups of Gay, Bisexual, and Other Men Who Have Sex with Men: A Latent Class Analysis of a Discrete Choice Experiment.AIDS Behav. 2024 Jan;28(1):125-134. doi: 10.1007/s10461-023-04131-y. Epub 2023 Jul 21. AIDS Behav. 2024. PMID: 37474623
-
Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.Lancet Glob Health. 2024 Feb;12(2):e243-e256. doi: 10.1016/S2214-109X(23)00536-3. Lancet Glob Health. 2024. PMID: 38245115
-
Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26107. doi: 10.1002/jia2.26107. J Int AIDS Soc. 2023. PMID: 37439057 Free PMC article. Review.
-
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.Drugs. 2022 Sep;82(14):1489-1498. doi: 10.1007/s40265-022-01791-3. Epub 2022 Oct 18. Drugs. 2022. PMID: 36255686 Review.
References
-
- AVAC. PrEP Watch: United States; 2022 [cited November 28, 2022]. Available from: https://www.prepwatch.org/country/united-states/ [Last accessed: June 6, 2023].
-
- Food and Drug Administration. Supplemental New Drug Application for Truvada for HIV Pre-exposure Prophylaxis. Department of Health and Human Services: Rockville, MD; 2018. [cited November 20, 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/021752Orig... [Last accessed: September 19, 2023].
-
- CDC. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data-United States and 6 Dependent Areas, 2020. HIV Surveill Suppl Rep 2022(3). Available from: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil... [Last accessed: June 6, 2023].
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous